Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis.
Journal
Science immunology
ISSN: 2470-9468
Titre abrégé: Sci Immunol
Pays: United States
ID NLM: 101688624
Informations de publication
Date de publication:
19 Apr 2024
19 Apr 2024
Historique:
medline:
19
4
2024
pubmed:
19
4
2024
entrez:
19
4
2024
Statut:
ppublish
Résumé
Vedolizumab (VDZ) is a first-line treatment in ulcerative colitis (UC) that targets the α4β7- mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) axis. To determine the mechanisms of action of VDZ, we examined five distinct cohorts of patients with UC. A decrease in naïve B and T cells in the intestines and gut-homing (β7
Identifiants
pubmed: 38640252
doi: 10.1126/sciimmunol.adg7549
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM